SynthesisFrontiers in immunology2025

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis.

Konstantinos Lallas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.